Half-Point Fed Hike Risk Raises Stakes for U.S. Stocks, Bonds and Housing
A possible half-point Fed hike is jolting expectations across stocks, bonds, mortgages, corporate credit and consumer lending.
JetBlue CEO Bets on Premium Strategy Despite Creditor Concerns
JetBlue is betting that premium offerings and new first-class seats can support its turnaround as cr…
Sabre Shares Jump on Report of Potential Travelport Combination
Sabre shares jumped after a report of a possible Travelport combination, putting GDS competition and…
Hot Inflation Data Sends Mortgage Rates Higher as Wall Street Rate-Cut Hopes Fade
Hotter inflation and hawkish Fed commentary pushed mortgage rates sharply higher, pressuring Wall St…
Retail Sales Growth Slows to Nearly One-Year Low as Consumer Strain Builds
October retail-sales growth slowed to a nearly one-year low, raising concerns about consumer strain,…
Altius Minerals’ $122 Million TNR Gold Deal Signals Fresh Canadian Mining Consolidation
Altius Minerals’ agreement to acquire TNR Gold for $122 million highlights renewed consolidation acr…
Reuters Poll Points to Another Fed Rate Hike as Inflation Risks Persist
A Reuters economist poll points to one more Fed rate hike in December, complicating expectations for…
Chip Stocks Rally Despite Nvidia Scandal as Traders Test a Potential Market Bottom
Chip stocks rallied despite Nvidia-related headlines, testing whether markets can form a bottom whil…
GFL Environmental Drops After Strategic Review Ends Without a Sale
GFL Environmental’s failed strategic review removes takeover speculation and highlights the risks of…
GFL Ends Strategic Review After Rejecting $52-a-Share Private Equity Offer
GFL Environmental rejected a $52-per-share private equity offer and ended its strategic review, remo…
Boeing’s 5% Workforce Cut Signals Slower Commercial-Airplane Recovery
Boeing’s planned 5% commercial-airplane workforce reduction underscores slower production recovery a…
LCI Board Rejects Revised Monomoy Buyout Bid, Keeping M&A Premium in Focus
LCI Industries rejected Monomoy’s revised non-binding proposal, underscoring valuation tension for m…
Goodyear’s CEO Exit Puts Turnaround Execution Under Interim Leadership
Goodyear’s CEO departure adds a new test to its turnaround as interim leader Roger Wood takes charge…
Markets
- RBC’s Australian Asset-Manager Deal Extends Its Global Wealth-Management Strategy
- Honda’s $3 Billion Ohio Hybrid Plant Signals a New Phase of U.S. Auto Investment
- UPS Reportedly Eyes $600 Million Smartways Logistics Acquisition
- Strathcona’s Up-to-C$2.9 Billion Greenfire Deal Extends Canadian Oil Sands Consolidation
Economy
- US Payrolls Beat and Canadian Jobs Miss Push USD/CAD Higher
- Payrolls Crush Expectations as Traders Reprice Fed Rate-Cut Bets
- Gold Jumps 3% as Dollar Weakens After Democratic Midterm Gains
- US Factory Orders Rise 1.8%, Beating Expectations in September
Analysis
- Airbnb Shares Rise 5.64% as Golden Cross Signals Renewed Technical Momentum
- Donchian Channel Breakout: 10-Year ETF Backtest
- MACD vs Moving Average Crossover: 9-Year SPY, QQQ Test
- ADX Trend Strength: What 10 Years of ETF Data Show
Earnings
- ConocoPhillips Raises Dividend After Earnings Beat as Oil Prices Support Results
- Utz Brands Reports Third-Quarter Results as Snack Investors Track Consumer Pressures
- Marathon Petroleum’s Earnings Beat Puts Refining Consolidation in the Spotlight
- Block Lifts Earnings Outlook as Cash App Strength Meets Preliminary DOJ Settlement
Technology
- Meta Executive’s Move to Fireworks Highlights Intensifying AI Talent War
- Palo Alto Networks’ Reported $500 Million Clutch Talks Put AI Security M&A in Focus
- CrowdStrike’s $495 Million AI Security Bet Puts Autonomous Defense in Focus
- Oracle’s $20 Billion Stock-and-Bond Fundraising Shows the Cost of the AI Buildout
IPO
- Anthropic IPO Filing Ignites Tech Rally While Founder Control Tests Investors
- TriGemX Bio’s $600 Million SPAC Merger Creates a New Nasdaq Biotech Watchlist Name
- XTEND AI Robotics: Analyzing the Market Implications of Its NYSE Debut
- Werewolf Therapeutics and Ambros' Merger: A New Era in Biotech